1 rich Libsyn https://www.libsyn.com 300 600 Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉 &amp;nbsp; A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects. &amp;nbsp; 📊 Signal: modest for weight loss, stronger for tolerability 🧠 Insight: genetics + clinical factors explain ~25% variability 🚀 Implication: early steps toward precision obesity therapeutics &amp;nbsp; The future may not be “one drug fits all,” but one genome, one strategy. Dr. RR Baliga's 'Podkast for the Kurious Doc' http://www.MasterMedFacts.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/40796650/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/200611015